Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

11/4/24 11:17:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYRX alert in real time by email

SC 13G/A 1 UnitedStates_13G__CryoPortIn.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* (Name of Issuer) CryoPort Inc (Title of Class of Securities) Common Stock (CUSIP Number) 229050307 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 229050307 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 70,460 (7) Sole dispositive power 2,726,546 (8) Shared dispositive power 112,357 (9) Aggregate amount beneficially owned by each reporting person 2,838,903 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.74% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: CryoPort Inc Item 1(b) Address of issuer's principal executive offices: 112 Westwood Place Suite 350 Brentwood, TN 37027 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 229050307 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 2,838,903 (b) Percent of class: 5.74% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 2,838,903 (b) Percent of class: 5.74% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 70,460 (iii) Sole power to dispose or to direct the disposition of: 2,726,546 (iv) Shared power to dispose or to direct the disposition of: 112,357 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on b

Get the next $CYRX alert in real time by email

Recent Analyst Ratings for

$CYRX

Date	Price Target	Rating	Analyst
8/7/2024	$20.00 → $8.00	Buy → Hold	Jefferies
7/31/2024	$19.00 → $15.00	Neutral → Buy	B. Riley Securities
5/3/2024	$22.00 → $19.00	Buy → Neutral	B. Riley Securities
4/4/2024	$17.00 → $21.00	Buy	Jefferies
3/13/2024	$19.00 → $18.00	Buy	Needham
8/17/2023	$16.00	Equal-Weight	Morgan Stanley
8/10/2023	$15.00	Overweight → Equal-Weight	Stephens
7/18/2023	$28.00 → $17.00	Buy → Neutral	UBS

More analyst ratings

Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

Chat with this insight

Recent Analyst Ratings for $CYRX

$CYRX Leadership Updates

Live Leadership Updates

Cryoport Announces Appointment of Linda Baddour to its Board of Directors

BriaCell Appoints Martin Schmieg to Board of Directors

$CYRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Hariri Robert J sold $9,465 worth of shares (1,000 units at $9.46), decreasing direct ownership by 4% to 23,061 units (SEC Form 4)

Director Hariri Robert J sold $17,395 worth of shares (2,000 units at $8.70), decreasing direct ownership by 8% to 23,561 units (SEC Form 4)

Director Mandalam Ramkumar exercised 4,167 shares at a strike of $5.04 and sold $33,520 worth of shares (4,167 units at $8.04) (SEC Form 4)

$CYRX Press Releases

Fastest customizable press release news feed in the world

Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024

Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services

TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics

$CYRX Large Ownership Changes

This live feed shows all institutional transactions in real time.